Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don\'t respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly prevent bone damage.The aim of this project is to test the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an existing treatment, methotrexate.
Epistemonikos ID: f4645818972c9b042f85fba4a5305a5e2a07c6d0
First added on: Mar 23, 2022